Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

50%(2 trials)

Phase Distribution

Ph not_applicable

25%

Ph phase_2

50%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

2(50.0%)

Phase 3Large-scale testing

1(25.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 22 (50.0%)

Phase 31 (25.0%)

N/A1 (25.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_3

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

NCT00085709

completedphase_2

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

NCT00176462

completedphase_2

High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)

NCT00136448

completednot_applicable

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

NCT00187122

Clinical Trials (4)

Showing 4 of 4 trials

NCT00085709Phase 3

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

Completed

NCT00176462Phase 2

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

Completed

NCT00136448Phase 2

High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)

Completed

NCT00187122Not Applicable

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4